Balanced news tone
News Sentiment
NVAX sentiment intelligence
Novavax Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-4.2% over one week, +5.1% over four weeks, trend active, and near fair-value range.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Novavax (NVAX) stock closed down 5.5% at $8.42, contrasting with general market gains. The company's shares also saw a 3.26% loss over the past month, while the Medical sector gained 4.34%. Analysts project a significant year-over-year decline in Novavax's upcoming earnings and r
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 21:45
- Source
- Market source
Novavax Inc. stock underperforms Tuesday when compared to competitors
Novavax Inc. (NVAX) stock fell by 5.50% on Tuesday, closing at $8.42, despite a generally positive trading day for the broader market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average saw gains, highlighting Novavax's underperformance. This marked the third co
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 14 Jul 2026 17:27
- Source
- MarketWatch
Novavax Inc. stock underperforms Monday when compared to competitors
Novavax Inc.'s stock (NVAX) fell 4.50% on Monday, closing at $8.91, amidst a general decline in the stock market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average also experienced losses, with NVAX marking its second consecutive day of decline.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 17:28
- Source
- MarketWatch
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Jul 2026 20:19
- Source
- Stocktwits
Novavax options trading jumps to highest in months By Investing.com
Novavax Inc. (NVAX) experienced a significant surge in options trading volume, reaching its highest levels in months on Friday. Call options hit a peak not seen since April 2024, while put options recorded their highest volume since December 2025, with two specific put options do
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 10 Jul 2026 17:44
- Source
- Investing.com Nigeria
Novavax options trading jumps to highest in months
Novavax Inc. experienced a significant surge in options trading volume, with 13,629 contracts traded by Friday afternoon. Call options reached their highest level since April 2024, and put options saw their highest volume since December 2025. This increased activity was predomina
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 16:41
- Source
- Investing.com
Enterprise value to EBIT forward of Novavax, Inc. – BMV:NVAX
This page from TradingView provides financial information for Novavax, Inc. (BMV:NVAX), specifically focusing on its enterprise value to EBIT forward. It indicates that the market is currently closed with no trades. The site also lists various other financial data, news, and comm
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 14:41
- Source
- TradingView
Novavax (NVAX) Leaves Russell Growth Indexes, Is The 32% Undervaluation Case Convincing?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 10 Jul 2026 05:15
- Source
- Simply Wall St.
Novavax (NVAX) Dropped From Major Russell Growth Indices And Why It Matters
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 03:24
- Source
- Market source
Novavax Inc. stock outperforms competitors despite losses on the day
Shares of Novavax Inc. (NVAX) fell 1.16% to $9.35, despite outperforming competitors on a mixed trading day where the NASDAQ Composite rose and the Dow Jones Industrial Average fell. The stock closed 21.89% below its 52-week high of $11.97, achieved on February 26th.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 21:24
- Source
- MarketWatch
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
Novavax (NVAX) experienced a larger daily drop of -1.16% compared to the S&P 500's -0.28%, despite recent gains in the Medical sector. The company is set to report earnings with a projected EPS of -$0.36 and revenue of $50.04 million, significantly down from the prior year. Howev
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 17:45
- Source
- Market source
Novavax Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Novavax Inc. (NVAX) shares increased by 1.18% to $9.46 on Tuesday, despite a general market downturn where the NASDAQ Composite fell 1.16% and the Dow Jones Industrial Average fell 0.25%. The stock is still 20.97% below its 52-week high of $11.97, reached on February 26th. This p
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 07 Jul 2026 17:26
- Source
- MarketWatch
Novavax Inc updates Covid-19 vaccine plans as investors weigh long-term prospects
Novavax Inc is adjusting its Covid-19 vaccine strategy, focusing on updated formulations and potential combination vaccines, as it navigates the shift from emergency pandemic demand to a more regular, seasonal vaccination market. Investors are closely watching regulatory decision
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 15:13
- Source
- AD HOC NEWS
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been a highly searched stock recently, with its shares returning +8.5% over the past month. The company currently holds a Zacks Rank #1 (Strong Buy), indicating potential near-term outperformance based on positive earnings estimate revisions. Despite this, proj
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 07 Jul 2026 13:13
- Source
- Market source
Does Novavax’s (NVAX) Russell Exit Quietly Recast Its Partnership-Driven, Royalty-Focused Equity Story?
Novavax (NVAX) was removed from several Russell growth indices on June 27, 2026, which may influence institutional investor behavior. This expert analysis explores how the index removal could reshape the perception of Novavax's partnership-driven, royalty-focused business model,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 06:39
- Source
- Sahm
If You Invested $1,000 in Novavax Inc (NVAX)
This article analyzes the historical performance of investing $1,000 in Novavax Inc (NVAX) over 1, 5, and 10 years, detailing significant fluctuations including a +2383.5% return in 2020 and sharp declines in other years. It also provides an overview of Novavax as a biotechnology
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 03:10
- Source
- Stock Titan
Novavax stock holds the focus as investors await the next catalyst.
Novavax (NVAX) stock remains a Nasdaq-listed vaccine company, with its shares primarily influenced by updates on commercialization, regulatory progress, and cash utilization. The article emphasizes that future market reactions will likely stem from company updates regarding deman
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 03 Jul 2026 13:40
- Source
- Ad-hoc-news.de
Novavax (NVAX) Stock Moves 1.36%: What You Should Know
Novavax (NVAX) stock recently moved up 1.36%, closing at $9.59. This movement contrasts with a prior 7.25% loss over the past month for the vaccine maker. Analysts anticipate a significant year-over-year decline in earnings and revenue for Novavax's upcoming report and the full y
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 21:39
- Source
- Market source
Novavax Inc. stock underperforms Thursday when compared to competitors despite daily gains
Novavax Inc. (NVAX) shares gained 2.96% on Thursday, closing at $9.74. Despite this daily increase, the stock underperformed compared to its competitors, even as the Dow Jones Industrial Average rose. This marked the fifth consecutive day of gains for Novavax stock.
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 02 Jul 2026 17:24
- Source
- MarketWatch
(NVAX) as a Liquidity Pulse for Institutional Tactics
This article analyzes Novavax Inc. (NASDAQ: NVAX) with a strong overweight bias based on robust sentiment across all time horizons. It highlights an exceptional 58.0:1 risk-reward setup, targeting a significant gain for investors. The analysis includes institutional trading strat
- Tone
- Positive 81/100
- Event
- Balance sheet
- Published
- 01 Jul 2026 19:02
- Source
- Stock Traders Daily
ETFs Investing in Novavax, Inc. Stocks
This article lists various ETFs that include Novavax, Inc. (NVV1) stocks in their holdings. The ETFs are sorted by market value and provide data such as market value, weight of NVV1 in the ETF, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 19:10
- Source
- TradingView
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose 5.41% on a strong trading day, closing at $9.36. This performance outpaced the broader market, with the NASDAQ Composite Index and Dow Jones Industrial Average also seeing gains. This marks the second day of consecutive gains for Novavax stock.
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 29 Jun 2026 17:29
- Source
- MarketWatch
Novavax, Inc.(NasdaqGS: NVAX) dropped from Russell 3000E Growth Benchmark
Novavax, Inc. (NasdaqGS: NVAX) has been removed from the Russell 3000E Growth Benchmark. This news comes amidst other recent company updates, including presentations at healthcare conferences and its first-quarter 2026 earnings report, which showed narrower-than-expected net loss
- Tone
- Negative 33/100
- Event
- Earnings
- Published
- 29 Jun 2026 03:13
- Source
- www.marketscreener.com
Novavax boosts efficiency and productivity with ServiceNow
Novavax partnered with NTT DATA to upgrade its ServiceNow platform, aiming to improve operational efficiencies and accommodate rapid growth, particularly following the success of its COVID-19 vaccine. The transformation involved upgrading to the "Tokyo" release, establishing a co
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 02:40
- Source
- NTT Data
Enterprise value to revenue forward of Novavax, Inc. – SIX:NVAX
This article briefly reports on the enterprise value to revenue forward for Novavax, Inc. (SIX:NVAX). It provides basic financial data and links to various tools and resources available on the TradingView platform related to market analysis. The content is sparse, primarily focus
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 02:38
- Source
- TradingView
How Investors May Respond To Novavax (NVAX) Shareholder Revolt Over Pay And Board Governance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 22:17
- Source
- simplywall.st
Enterprise value to EBITDA forward of Novavax, Inc. – SIX:NVAX
This article examines the enterprise value to EBITDA forward for Novavax, Inc. (NVAX) on the SIX Swiss Exchange. It provides financial transparency but does not offer specific values or analysis. The brief page is part of a larger financial data platform.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 22:40
- Source
- TradingView
Novavax Inc. stock underperforms Friday when compared to competitors despite daily gains
Novavax Inc. (NVAX) shares rose 3.74% on Friday, closing at $8.88, despite a broader market downturn with the NASDAQ Composite and Dow Jones Industrial Average both falling. This gain ended a two-day losing streak for Novavax, though the stock was noted to underperform when compa
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 26 Jun 2026 21:40
- Source
- MarketWatch
Enterprise value to revenue forward of Novavax, Inc. – NASDAQ:NVAX
This article focuses on the enterprise value to revenue forward metric for Novavax, Inc. (NASDAQ: NVAX). The provided content is from TradingView and includes financial data and stock market information for the biotechnology company.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:40
- Source
- TradingView